Analysts Offer Predictions for BridgeBio Pharma, Inc.’s FY2027 Earnings (NASDAQ:BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Stock analysts at Leerink Partnrs decreased their FY2027 EPS estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Thursday, August 1st. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of $2.56 per share for the year, down from their previous forecast of $2.85. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.20) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s FY2028 earnings at $5.38 EPS.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.61. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $3.96 million. During the same period in the prior year, the firm posted ($0.98) EPS. The business’s revenue was up 32.1% on a year-over-year basis.

Several other brokerages have also commented on BBIO. Cantor Fitzgerald restated an “overweight” rating and set a $70.00 price target on shares of BridgeBio Pharma in a research note on Monday, July 1st. UBS Group cut their target price on shares of BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating on the stock in a research report on Tuesday, May 28th. Bank of America lowered their price target on shares of BridgeBio Pharma from $50.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, June 25th. Evercore ISI initiated coverage on shares of BridgeBio Pharma in a report on Tuesday, May 14th. They set an “outperform” rating and a $50.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $43.00 target price on shares of BridgeBio Pharma in a report on Monday. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has an average rating of “Buy” and a consensus price target of $48.73.

BridgeBio Pharma Stock Down 2.5 %

Shares of NASDAQ BBIO opened at $24.87 on Monday. BridgeBio Pharma has a twelve month low of $21.62 and a twelve month high of $44.32. The firm has a market cap of $4.65 billion, a PE ratio of -7.72 and a beta of 1.06. The business has a fifty day simple moving average of $26.69 and a two-hundred day simple moving average of $29.19.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Quest Partners LLC acquired a new position in BridgeBio Pharma during the 2nd quarter valued at approximately $337,000. Arizona State Retirement System increased its position in shares of BridgeBio Pharma by 7.6% in the 2nd quarter. Arizona State Retirement System now owns 30,857 shares of the company’s stock valued at $782,000 after acquiring an additional 2,171 shares during the period. Victory Capital Management Inc. increased its position in shares of BridgeBio Pharma by 9.9% in the 2nd quarter. Victory Capital Management Inc. now owns 382,717 shares of the company’s stock valued at $9,694,000 after acquiring an additional 34,360 shares during the period. Rhumbline Advisers raised its stake in BridgeBio Pharma by 19.5% in the 2nd quarter. Rhumbline Advisers now owns 221,403 shares of the company’s stock worth $5,608,000 after acquiring an additional 36,199 shares during the last quarter. Finally, Mizuho Markets Americas LLC lifted its position in BridgeBio Pharma by 13.0% during the 2nd quarter. Mizuho Markets Americas LLC now owns 83,982 shares of the company’s stock worth $2,127,000 after acquiring an additional 9,673 shares during the period. 99.85% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Randal W. Scott sold 1,000 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $28.84, for a total value of $28,840.00. Following the completion of the sale, the director now directly owns 5,500 shares in the company, valued at $158,620. The transaction was disclosed in a document filed with the SEC, which is available at this link. 24.66% of the stock is owned by company insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.